Vaccine

Details Vaccine Vaccine

2007-09-25

2007-09-25

Kaushal, Sumesh (Department: 1633)

Drug, bio-affecting and body treating compositions

Whole live micro-organism, cell, or virus containing

Genetically modified micro-organism, cell, or virus

C424S190100, C424S199100, C424S232100, C424S272100, C424S093300, C424S184100, C435S456000, C435S069300, C435S320100, C435S455000

Reexamination Certificate

active

10856118

ABSTRACT:
The present invention relates to a fowlpox virus genome which has modifications in one or more wild-type FPV genes. The present invention also relates to a viral particle comprising such a genome and its use to deliver a nucleotide of interest (NOI) to a target cell. The present invention also relates to vaccination methods, particularly a method which comprises administering a priming composition (which comprises a first non-replicating viral vector) and a boosting composition (which comprises a second non-replicating viral vector) to a subject to treat and/or prevent a disease.

REFERENCES:
patent: 4053582 (1977-10-01), Stickl
patent: 4748019 (1988-05-01), Lysons
patent: 5110587 (1992-05-01), Paoletti et al.
patent: 5185146 (1993-02-01), Altenburger
patent: 5225336 (1993-07-01), Paoletti
patent: 5453364 (1995-09-01), Paoletti
patent: 5462734 (1995-10-01), Letchworth, III et al.
patent: 5766597 (1998-06-01), Paoletti et al.
patent: 5846546 (1998-12-01), Hurwitz et al.
patent: 6103244 (2000-08-01), Dorner et al.
patent: 6663871 (2003-12-01), McMichael et al.
patent: 2003/0138454 (2003-07-01), Hill et al.
patent: 2004/0018177 (2004-01-01), Hill et al.
patent: 2004/0131594 (2004-07-01), McMichael et al.
patent: 2004/0175365 (2004-09-01), McMichael et al.
patent: 2004/0191272 (2004-09-01), McMichael et al.
patent: 2004/0197349 (2004-10-01), McMichael et al.
patent: 2004/0213799 (2004-10-01), McMichael et al.
patent: 2005/0175627 (2005-08-01), Schneider
patent: 0 638 316 (1995-02-01), None
patent: 0 753 581 (1997-01-01), None
patent: 0517292 (2000-02-01), None
patent: WO92/22641 (1992-12-01), None
patent: WO93/03145 (1993-02-01), None
patent: WO96/26271 (1996-08-01), None
patent: WO97/39771 (1997-10-01), None
patent: WO98/04728 (1998-02-01), None
patent: WO98/56919 (1998-12-01), None
patent: WO9856919 (1998-12-01), None
patent: WO 01/02607 (2001-01-01), None
patent: WO 01/14416 (2001-03-01), None
patent: WO 01/85932 (2001-11-01), None
patent: WO 01/85932 (2001-11-01), None
patent: WO 02/068654 (2002-09-01), None
patent: WO 02/068654 (2002-09-01), None
patent: WO 2005/030964 (2005-04-01), None
Laidlaw, S.M. et al., “Comparison of the genome sequence of FP9, and attenuated, tissue culture-adapted European strain of Fowlpox virus, with those of virulent American and European viruses”, 2004, J. Gen. Virol., vol. 85: pp. 305-322.
Schneider, J. et al., “Induction of CD8+ T cells using heterologous prime-boost immunisation strategies”, 1999, Immunological Rev., vol. 170: pp. 29-38.
Skinner, M.A. et al., “Fowlpox virus as a recombinant vaccine vector for use in mammals and poultry”, 2005, Expert Rev. Vaccines, vol. 4: pp. 63-76.
Carvalho, L.J.M. et al., “Malaria Vaccine: Candidate Antigens, Mechanisms, Constraints and Prospects”, 2002, Scand. J. Immunol., vol. 56: pp. 327-343.
Carter, B., “Gene Therapy as Drug Development”, 2000, Mol. Therapy, vol. 1: pp. 211-212.
Holder, A. et al., “Faliciparum Malaria MSP1 Workshop Progress toward MSP1 Vaccine Development and Testing”, 2000, Malaria Vaccine Initiative, pp. 1-30.
Niewiesk, S. et al., “Measles Virus-Induced Immune Suppression in the Cotton Rat (Sigmodon hispidus) Model Depends on Viral Glycoproteins”, 1997, J. Virol., vol. 71: pp. 7214-7219.
Afonso, et al., NCBI Accession No. AF198100,J. Virology 74(8):3815-3831 (2000).
Anderson, et al., “Enhanced CD8 T Cell Response and Protective Efficacy Against Malaria Using Recombinant Fowlpox Virus In Heterologous Prime/Boost Immunisation Regimes,” Abstract,Immunology 101(Supplement 1):32 (2000).
Hodge, James W., et al., “Diversified Prime and Boost Protocols Using Recombinant Vaccinia Virus and Recombinant Non-Replicating Avian Pox Virus to Enhance T-Cell Immunity and Antitumor Responses,”Vaccine 15(6-7):759-768 (1997).
Tsukamoto, Kenji, et al., “Dual-Viral Vector Approach Induced Strong and Long-Lasting Protective Immunity Against Very Virulent Infectious Bursal Disease Virus,”Virology 269(2):257-267 (2000).
Irvine, K.R., et al., “Enhancing Efficacy of Recombinant Anticancer Vaccines with Prime/Boost Regiments That Use Two Different Vectors,”J. Natl. Cancer Institute 89(21):1595-1601 (1997).
Taylor, J. And Paoletti, E., “Fowlpox Virus As A Vector in Non-Avian Species,”Vaccine 6:466-468 (1988).
Taylor, J., et al., “Recombinant Fowlpox Virus Inducing Protective Immunity in Non-Avian Species,”Vaccine 6(6):497-503 (1988).
Afonso, C.L., et al., “The Genome of Fowlpox Virus,”J. Virology 74(8):3815-3831 (2000).
Shaw, I., and Davison, T.F., “Protection From IBDV-Induced Bursal Damage By A Recombinant Fowlpox Vaccine, fplBD1, Is Dependent ON the Titre of Challenge Virus and Chicken Genotype,”Vaccine18:3230-3241 (2000).
Boulanger, D., et al., “The 131-Amino-Acid Repeat Region of the Essential 39-Kilodalton Core Protein of Fowlpox Virus FP9, Equivilant to Vaccinia Virus A4L Protein, Is Nonessential and Highly Immunogenic,”J. Virol 72(1):170-179 (1998).
Boulanger, D., et al., “Morphogenesis and Release of Fowlpox Virus,”J. of Gen. Virol. 81:675-687 (2000).
Laidlaw, S. M., et al., “Fowlpox Virus Encodes Nonessential Homologs of Cellular Alpha-SNAP, PC-1, and an Orphan Human Homolog of a Secreted Nematode Protein,”J. Virol. 72(8):6742-6751 (1998).
Dale, C. J., et al., “Induction of HIV-1-Specific T-Helper Responses and Type 1 Cytokine Secretion Following Therapeutic Vaccination of Macaques with A Recombinant Fowlpoxvirus Co-expressing Interferon-Gamma,”J. Med. Primatol. 29:240-247 (2000).
Kent, S. J., et al., “Enhanced T-Cell Immunogenicity and Protective Efficacy of a Human Immunodeficiency Virus Type 1 Vaccine Regimen Consisting of Consecutive Priming with DNA and Boosting with Recombinant Fowlpox Virus,”J. Virol. 72(12):10180-10188 (1998).
Boursnell, M. E. G., et al., “a Fowlpox Virus Vaccine Vector with Insertion Sites in the Terminal Repeats: Demonstration of its Efficacy Using the Fusion Gene of Newcastle Disease Virus,”Veterin. Microbiology 23:305-316 (1990).
Boursnell, M. E. G., et al., “Insertion of the Fusion Gene from Newcastle Disease Virus into a Non-essential Region in the Terminal Repeats of Fowlpox Virus and Demonstration of Protective Immunity Induced by the Recombinant,”J. Gen. Virology 71:621-628 (1990).
Boyle, D. B. And Heine, H. G., “Recombinant Fowlpox Virus Vaccines for Poultry,”Immunol and Cell Biol. 71:391-397 (1993).
Boyle, D. B., et al., “Comparison of Field and Vaccine Strains of Australian Folwpox Viruses,”Arch Virol 142:737-748 (1997).
Brooks, J. V., et al., “Boosting Vaccine for Tuberculosis,”Infection and Immunity 69(4): 2714-2717 (2001).
Campbell, J. I. A., et al., “Tandem Repeated Sequences Within the Terminal Region of the Fowlpox Virus Genome,”J. Gen. Virol. 70:145-154 (1989).
Grosenbach, D. W., et al., “Synergy of Vaccine Strategies to Amplify Antigen-specific Immune Responses and Antitumor Effects,”Cancer Res 61:4497-4505 (2001).
Hertig, C., et al., “Field and Vaccine Strains of Fowlpox Virus Carry Integrated Sequences from the Avian Retrovirus, Reticuloendotheliosis Virus,”Virol. 235:367-376 (1997).
Irvine, K. R., et al., “Route of Immunization and the Therapeutic Impact of Recombinant Anticancer Vaccines,”J. of the Natl. Cancer Inst. 89(5):390-392 (1997).
Kent, S. J., et al., A Recombinant Avipoxvirus HIV-1 Vaccine Expressing Interferon-gamma is Safe and Immunogenic in Macaques,Vaccine 18:2250-2256 (1999).
Gilbert, S. C., et al., “A Protein Particle Vaccine Containing Multiple Malaria Epitopes,”Nature Biotechnology 15:1280-1284 (1997).
Mahnel, et al., “Experiences with Immunization Against Orthopox Viruses of Humans and Animals Using Vaccine Strains MVA,”Berliner Und Munchener Tierarztliche Wochenschrift 107(8):253-256 (1994) Abstract Only.
Meyer

Affiliated with

Also associated with

Rating

Vaccine does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Vaccine, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Vaccine will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3771857